Tideglusib
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
15
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Congenital Myotonic Dystrophy
Conditions
Congenital Myotonic Dystrophy
Trial Timeline
— → —
NCT ID
NCT07119775About Tideglusib
Tideglusib is a pre-clinical stage product being developed by AMO Pharma for Congenital Myotonic Dystrophy. The current trial status is active. This product is registered under clinical trial identifier NCT07119775. Target conditions include Congenital Myotonic Dystrophy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
2
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07119775 | Pre-clinical | Active |
| NCT05004129 | Phase 2/3 | Recruiting |
| NCT02858908 | Phase 2 | Completed |
Competing Products
20 competing products in Congenital Myotonic Dystrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| EDIT-101 | Editas Medicine | Phase 1/2 | 33 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| SPR001 | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont/Placebo | Spruce Biosciences | Phase 2 | 44 |
| Tildacerfont | Spruce Biosciences | Phase 2 | 44 |
| KW-3357 | Kyowa Kirin | Phase 1 | 33 |
| Pasireotide 0.6Mg Solution for Injection + Saline Solution | Novartis | Phase 2 | 52 |
| Sandostatine LP | Novartis | Phase 2 | 52 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| turoctocog alfa + turoctocog alfa | Novo Nordisk | Phase 3 | 76 |
| catridecacog + recombinant factor XIII | Novo Nordisk | Phase 1 | 32 |
| activated recombinant human factor VII | Novo Nordisk | Phase 2 | 51 |
| turoctocog alfa pegol | Novo Nordisk | Phase 3 | 76 |
| recombinant factor XIII | Novo Nordisk | Pre-clinical | 22 |
| activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting | Novo Nordisk | Phase 1 | 32 |
| Advate® + turoctocog alfa | Novo Nordisk | Phase 1 | 32 |
| nonacog beta pegol | Novo Nordisk | Phase 3 | 76 |